Highlights

• Q4 FY26 net profit declined sharply due to lower US sales and high base effect
  • Company continues expanding semaglutide portfolio across India and Canada
  • Investors tracking future growth opportunities in obesity and diabetes treatment markets

Overview

Dr. Reddy's Laboratories Limited (NSE: DRREDDY) remained in focus after reporting a sharp decline in Q4 FY26 profitability, even as the company continued strengthening its position in the rapidly growing GLP-1 and obesity drug segment. The stock traded near ₹1,274.00 on May 13, 2026, recovering from intraday volatility after the earnings announcement.

The pharmaceutical major reported weaker quarterly earnings primarily because of lower contribution from key US products and a significantly high base from the previous year. However, management commentary and recent strategic developments around semaglutide products continued to attract investor attention despite the softer quarterly performance.

Market participants are now closely watching whether new product launches and expansion into high-growth therapy areas can support earnings recovery in FY27.

Fundamental View

The company reported Q4 FY26 net profit of around ₹220.00 crore, reflecting a steep decline compared to the strong profit base recorded in the corresponding quarter last year. Revenue also witnessed pressure during the quarter amid moderation in the US generics business.

The weaker profitability was largely linked to pricing pressure, lower contribution from certain products in overseas markets, and normalization after an exceptionally strong prior-year period. Despite this, the company continues to maintain a diversified pharmaceutical portfolio spanning generics, APIs, biosimilars, and specialty therapies.

A major area of focus remains the GLP-1 and obesity drug segment. The company recently expanded its semaglutide portfolio after launching generic semaglutide products in India and preparing for additional launches in international markets. The approval received in Canada for generic semaglutide products has further strengthened expectations around future growth opportunities.

The broader pharmaceutical sector is also witnessing rising investor interest in obesity treatment therapies, creating a long-term structural opportunity for companies with early positioning in this segment.

What the GLP-1 Strategy Signals

The aggressive push into GLP-1 therapies suggests that the company is aiming to diversify future growth drivers beyond traditional generics. Global demand for diabetes and obesity-related drugs has increased significantly over the last few years, with semaglutide-based products emerging as one of the fastest-growing therapy categories worldwide.

By entering both injectable and oral semaglutide markets, the company is positioning itself to benefit from rising healthcare demand across multiple regions. Expansion into Canada also indicates an effort to strengthen its international specialty business while reducing dependence on a few mature markets.

Investors are now assessing whether these initiatives can gradually offset pricing pressure and volatility in the core generics business.

Technical View

Dr. Reddy's Laboratories Limited (NSE: DRREDDY) is trading near ₹1,274.00 and remains close to its 50-day SMA around ₹1,275.49, indicating a relatively balanced near-term structure. Price action reflects consolidation after recent volatility, with the stock attempting to stabilize above the ₹1,230.00 zone.

The 14-day RSI is positioned near 48.88, suggesting neutral momentum conditions without strong directional bias at current levels.

Immediate support is placed around ₹1,200.00–₹1,145.00, while resistance is seen near ₹1,330.00–₹1,400.00. A sustained move above the upper resistance zone could improve near-term sentiment, while weakness below support levels may increase pressure on the stock.

Latest News

The company recently secured approval for generic semaglutide products in Canada, expanding its international footprint in obesity and diabetes care therapies. It also continued rolling out semaglutide-related products in India as part of its broader GLP-1 expansion strategy.

At the same time, management clarified that reports regarding large-scale workforce cost reductions were inaccurate, helping ease concerns around operational restructuring.

The company is expected to focus heavily on specialty products, new launches, and regulated market expansion during FY27.

Key Risks

• Continued pricing pressure in the US generics market
  • Slower-than-expected commercialization of semaglutide products
  • Regulatory risks across international pharmaceutical markets
  • Margin volatility due to product mix changes and competition

Summary

Dr. Reddy's Laboratories Limited (NSE: DRREDDY) is currently navigating a transition phase where near-term earnings pressure is being balanced against long-term growth opportunities in obesity and diabetes therapies. While Q4 FY26 earnings disappointed the market, the company’s aggressive expansion into semaglutide and GLP-1 products continues to keep investors optimistic about future growth potential.

The coming quarters are likely to remain important as markets assess whether new product launches and international expansion can support revenue recovery and improve profitability momentum.

FAQs

Why did Dr. Reddy's Laboratories profit decline in Q4 FY26?
Profit declined mainly because of weaker US sales, pricing pressure, and a high base effect from the previous year.

What is driving future growth expectations for the company?
Expansion into semaglutide and GLP-1 therapies across India and international markets is driving long-term growth expectations.

What are the important technical levels for the stock?
Support is placed around ₹1,200.00–₹1,145.00, while resistance is positioned near ₹1,330.00–₹1,400.00.